# OnCo record her2-low-metastatic-breast-cancer (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/her2-low-metastatic-breast-cancer/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "her2-low-metastatic-breast-cancer" ;
  schema:name "HER2-low and HER2-ultralow metastatic breast cancer"@en ;
  schema:alternateName "HER2 IHC 1+ or 2+ ISH-negative breast cancer"@en, "Metastatic breast cancer with low HER2 expression"@en ;
  schema:description "HER2-low is not a new kind of breast cancer but a new way of reading an old test: tumours once called HER2-negative that carry a little HER2 protein. That trace is enough for the antibody-drug conjugate trastuzumab deruxtecan to deliver its chemotherapy payload, and since 2022 it has been the standard for these patients after endocrine therapy or a first chemotherapy."@en ;
  schema:url <https://onco.cc/cancers/her2-low-metastatic-breast-cancer/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan> ;
  schema:citation <https://doi.org/10.1056/NEJMoa2203690>, <https://clinicaltrials.gov/study/NCT04494425>, <https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan> ;
  onco:tag "subtype-page" ;
  onco:keyPapers <https://onco.cc/key-papers/paper-destiny-breast06-nejm-2024/> ;
  onco:pipeline <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/trastuzumab-rezetecan/>, <https://onco.cc/drugs/disitamab-vedotin/>, <https://onco.cc/technologies/her2-pet/>, <https://onco.cc/drugs/datopotamab-deruxtecan/> ;
  onco:standardOfCare <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/destiny-breast06/>, <https://onco.cc/terms/her2-low/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/destiny-breast04/>, <https://onco.cc/terms/her2-low/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/trials/ascent/>, <https://onco.cc/trials/tropion-breast02/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/terms/ild/> .